Nov 12, 2020/by 3mediawebEpygenix Therapeutics Announces First Patient Successfully Dosed in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100
Oct 2, 2020/by 3mediawebEpygenix Therapeutics Announces First Patient Enrolled in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100
Sep 17, 2020/by 3mediawebEpygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100
Jan 27, 2020/by 3mediawebEpygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies
Jul 29, 2019/by 3mediawebEpygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome
Jun 24, 2019/by 3mediawebEpygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome
Aug 23, 2017/by 3mediawebEpygenix Therapeutics Receives US FDA Orphan Drug Designation For EPX-300 For The Treatment Of Patients With Dravet Syndrome.
Jun 8, 2017/by 3mediawebProfile of Epygenix Therapeutics is listed in June 2017 issue of Biopharma Dealmakers – Published in Nature Reviews Drug Discovery & Nature Biotechnology
